Short answer
Autolus Therapeutics plc (AUTL) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities). $75.0M drawn July 30, 2026 under senior secured facility, with up to $175.0M additional availability.
Autolus Therapeutics plc 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $75.0M drawn July 30, 2026 under senior secured facility, with up to $175.0M additional availability
- Debt matures July 30, 2031, with monthly interest at 6.75%-7.25% plus greater of one-month SOFR or 3.50%
- No scheduled principal amortization, but substantially all company and guarantor assets secure repayment
- Liquidity covenants require $12.5M-$50.0M minimum liquidity and specified Consolidated Net Revenue levels
- Perceptive received warrants for 3,500,000 ADSs at $1.9314, with potential additional warrants for 5,000,000 ADSs tied to later tranches
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 links to the Perceptive Senior Secured Notes Facility described under Item 1.01
- New senior secured debt creates a direct financial obligation and may increase leverage
- Investors should review Item 1.01 for principal amount, interest rate, maturity and collateral terms
Item 3.02 · Unregistered Sales of Equity Securities
- Perceptive Warrants terms under Item 1.01 govern this unregistered equity issuance
- Potential dilution and ownership impact depend on warrant shares and exercise terms disclosed in the incorporated section
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Autolus Therapeutics plc 8-K filings
Get the next AUTL 8-K as it lands
Follow AUTL for push alerts, or ask the research agent what this filing means.